

available at www.sciencedirect.comjournal homepage: www.ejcancer.info

Invited Publications

Thursday, 22 March, 08:30–10:30

Session I. Multimodal Approach to Rectal Cancer

PG 1.01 SPEAKER ABSTRACT Rectal cancer: what is the aim of multimodal therapy?

D. Arnold. Hubertus Wald Cancer Center, Hamburg, Germany

No abstract available.

PG 1.02 SPEAKER ABSTRACT Clinically relevant study end points in rectal cancer

C. Fernandez-Martos. Oncology, Seccion de Oncologia Gastrointestinal, Fundacion Instituto Valenciano de Oncologia, Valencia, Spain

For multiple reasons, including complexities in anatomy, report in histopathological examination, local staging techniques limitations, and management, locally advanced rectal cancer represent a challenging disease for the design of clinical trials and for reporting of end points. In rectal cancer currently there is no validated any early end point as surrogate for long-term clinical outcome such as local control and survival. However the use of some kind of response rate (i.e. Pathological complete response, downsizing the primary tumor, tumor regression rate, Radiological response ...) as an endpoint in early (phase II) clinical trials is widespread for the obvious reason that objective response to therapy is a clear early indication of activity. Overall survival is the gold standard primary end point in phase III adjuvant clinical trials. However the long follow up needed to observe reliable results and the increasing number of effective salvage treatments available that may confuse the merits of the experimental treatment, have prompted the search for earlier surrogates end points. In adjuvant colon cancer disease-free survival – defined as the time from randomization to any event, irrespective of cause – have been validated as surrogate for overall survival and is considered to be the most informative endpoint for assessing the effect of treatment and therefore the most relevant to clinical practice. Although never validated in the locally advanced rectal cancer, DFS has been proposed as an appropriate end point in adjuvant rectal cancer trials, and is actually the most frequently used in newer trials. Due to the particularly devastating nature of local recurrence in locally advanced rectal cancer, local control (which is itself a subset of the overall DFS endpoint) is still considered an important endpoint. Recently circumferential resection margin (CRM/R0) has been proposed as novel candidate for early end point because the CRM status can substantially account for effects on disease-free and overall survival after chemoradiation, radiation or surgery alone, but again need a formal validation for long-term outcomes. An effort of consensus is needed among clinicians and methodologists to define the most appropriate end points in both early and phase III trials in LAR cancer.

PG 1.03 SPEAKER ABSTRACT Neoadjuvant treatment: Do we need radiotherapy?

R. Glynn-Jones. Gastrointestinal Cancer, Mount Vernon Cancer Centre, Northwood, United Kingdom

Historically, in locally advanced rectal cancer there has been a high local recurrence rate, but with total mesorectal excision (TME), metastatic disease is now the predominant problem, reflecting the likely presence of micrometastases at diagnosis, rather than inadequate surgery. In resectable rectal cancer, modern randomised studies show chemoradiation (CRT) or short course preoperative radiotherapy (SCPRT) reduce locoregional failure (LRF), without improving disease-free survival (DFS) or overall survival (OS) (Peeters 2007, Sebag-Montefiore 2009, Sauer 2004, Bosset 2006, Gerard 2006, van Gijn 2011) [1–6]. SCPRT and CRT appear equivalent in terms of local recurrence, DFS and OS (Bujko 2006, Ngan 2010) [7,8]. Trials integrating oxaliplatin into CRT have not increased the pathological complete response

rate (pCR) but suggest the use of two drugs halves the positive CRM rate (Gerard 2010, Aschele 2011) [9,10]. For unresectable/locally recurrent cases, 5FU-based CRT significantly improves resectability and relapse-free survival compared to RT alone (Braendengen 2008) [11]. In stage III patients with colon cancer, adjuvant oxaliplatin improves 3-year DFS compared to 5-FU/folinic acid alone (Kuebler 2007, André 2009) [12,13]. However, rectal cancers (within 12 cm of the anal verge) have been excluded from these studies, and so the role of adjuvant postoperative chemotherapy in rectal cancer after preoperative CRT is controversial (Bujko 2010) [14]. There is a high risk of metastatic disease in locally advanced rectal cancer, yet systemically active doses of chemotherapy are not delivered in CRT schedules, and compliance to postoperative adjuvant chemotherapy is generally poor. Hence, some groups have added chemotherapy either prior to CRT, when compliance to chemotherapy is high (Fernandez-Martos 2010) [15], or following chemoradiation to increase the response rate (Garcia-Aguilar 2011) [16]. Some groups have suggested this strategy leads to excellent long-term results, but raise concerns for a high early death rate (Chua 2010) [17]. Pelvic radiotherapy causes permanent morbidity in about 5–10% of patients, and impacts on small bowel function, sexual functioning, urinary incontinence, bowel function (Peeters 2005) [18], and an increase in faecal incontinence (Lange 2007) [19]. There is an increased risk of a second malignancy (Birgisson 2005, Van Gijn 2011) [20,6]. These complications are likely to be similar after preoperative CRT (Ngan 2010) [8]. In contrast to radiotherapy, the side effects of chemotherapy are usually short-term, although the neuropathy from oxaliplatin may be permanent. Several groups have explored omitting radiotherapy when MRI suggests the tumour is easily resectable. This omission does not appear to have increased the local recurrence rate (Taylor 2011, Frasson 2011, Mathis 2012) [21–23]. Three feasibility/retrospective studies of neoadjuvant chemotherapy (NACT) alone without radiation (Cercek 2010, Schrag 2010, Ishii 2010) [24–26] used FOLFOX plus/minus bevacizumab. The pCR rate after chemotherapy alone varied from 7%–35%, but as small non-randomised studies are unable to show an impact on metastatic disease. Chemotherapy at systemically-effective doses aims to reduce the risk of metastases. For unresectable cancers or where MRI shows a threatened/breached CRM (10–15% of cases), radiation as a component of CRT is clearly required. Chemotherapy prior to CRT or SCPRT does not compromise the delivery CRT, but has not increased pCR rates, R0-resection rate, improved DFS or reduced metastases. There is significant late morbidity from pelvic radiotherapy and a doubling of the risk of second malignancy. Hence NACT alone without radiotherapy could be explored compared with SCPRT or CRT in selected patients with resectable rectal cancer showing adverse features (extramural vascular invasion etc.) in a future research programme. In the UK, current NICE clinical guidelines have set NACT strategies as a priority of future research in rectal cancer, <http://guidance.nice.org.uk/CG131> However, large well-conducted carefully imaged randomised phase III trials comparing chemotherapy alone with the current standard of SCPRT or CRT will be required if we are to provide definitive answers.

Reference(s)

- [1] Peeters KC, Marijnen CA, Nagtegaal ID, et al., for the Dutch Colorectal Cancer Group. The TME Trial after a Median Follow-up of 6 Years: Increased local control but no survival benefit in irradiated patients with resectable rectal Carcinoma. *Ann Surg* 2007; 246(5): 693–701.
- [2] Sebag-Montefiore D, Stephens RJ, Steele R, et al., Preoperative radiotherapy versus selective postoperative chemoradiotherapy in patients with rectal cancer (MRC CR07 and NCIC-CTG C016): a multicentre, randomised trial. *Lancet* 2009;373(9666):811–20.
- [3] Sauer R, Becker H, Hohenberger W, et al., German Rectal Cancer Study Group. Preoperative versus postoperative chemoradiotherapy for rectal cancer. *N Engl J Med* 2004; 351:1731–1740.
- [4] Bosset JF, Collette L, Calais G, et al., Chemoradiotherapy with preoperative radiotherapy in rectal cancer. *N Engl J Med* 2006; 355: 1114–1123.

- [5] Gerard JP, Conroy T, Bonnetain F, et al., Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-T4 rectal cancers: results of FFCD 9203. *J Clin Oncol* 2006; 24:4620–4625.
- [6] van Gijn W, Marijnen CA, Nagtegaal ID, et al., Dutch Colorectal Cancer Group. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer: 12-year follow-up of the multicentre, randomised controlled TME trial. *Lancet Oncol*. 2011;12(6):575–82.
- [7] Bujko K, Nowacki MP, Nasierowska-Guttmejer A, et al., Long-term results of a randomized trial comparing preoperative short-course radiotherapy with preoperative conventionally fractionated chemoradiation for rectal cancer. *Br J Surg*. 2006;93(10):1215–23.
- [8] Ngan S, Fisher R, Goldstein D et al., TROG, AGITG, CSSANZ, and RACS. A randomized trial comparing local recurrence (LR) rates between short-course (SC) and long-course (LC) preoperative radiotherapy (RT) for clinical T3 rectal cancer: An intergroup trial (TROG, AGITG, CSSANZ, RACS). *J Clin Oncol* 2010 28: (15 Suppl) abstract 3509.
- [9] Gerard JP, Azria D, Gourgou-Bourgade S, et al. Comparison of two neoadjuvant chemoradiotherapy regimens for locally advanced rectal cancer: results of the Phase III trial ACCORD 12/0405-ProDIGe 2. *J Clin Oncol* 2010;28:1638–44.
- [10] Aschele C, Cionini L, Lonardi S et al. Primary tumor response to preoperative chemoradiation with or without oxaliplatin in locally advanced rectal cancer: pathologic results of the STAR-01 randomized phase III trial. *J Clin Oncol*. 2011 Jul 10;29(20):2773–80.
- [11] Braendengen M, Tveit KM, Berglund A, Birkemeyer E, Frykholm G, Pahlman L, Wiig JN, Byström P, Bujko K, Glimelius B. Randomized phase III study comparing preoperative radiotherapy with chemoradiotherapy in nonresectable rectal cancer. *J Clin Oncol*. 2008;26(22):3687–94.
- [12] Kuebler JP, Wieand HS, O'Connell MJ et al., Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07. *J Clin Oncol* 2007;25(16):2198–204.
- [13] André T, Boni C, Navarro M, et al., Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. *J Clin Oncol*. 2009;27(19):3109–16.
- [14] Bujko K, Glynne-Jones R, Bujko M. Does adjuvant fluoropyrimidine? Does adjuvant fluoropyrimidine-based chemotherapy provide a benefit for patients with resected rectal cancer who have already received neoadjuvant radiochemotherapy? A systematic review of randomised trials. *Ann Oncol*. 2010;21(9):1743–50.
- [15] Fernández-Martos C, Pericay C, Aparicio J, et al., Phase II, Randomized Study of Concomitant Chemoradiation Followed by Surgery and Adjuvant Capecitabine Plus Oxaliplatin (CAPOX) Compared With Induction CAPOX Followed by Concomitant Chemoradiation and Surgery in Magnetic Resonance Imaging-Defined, Locally Advanced Rectal Cancer: Grupo Cancer de Recto 3 Study. *J Clin Oncol*. 2010;28(5):859–65.
- [16] Garcia-Aguilar J, Smith DD, Avila K, et al., Timing of Rectal Cancer Response to Chemoradiation Consortium. Optimal timing of surgery after chemoradiation for advanced rectal cancer: preliminary results of a multicenter, nonrandomized phase II prospective trial. *Ann Surg*. 2011;254(1):97–102.
- [17] Chua YJ, Barbachano Y, Cunningham D, et al., Neoadjuvant capecitabine and oxaliplatin before chemoradiation and total mesorectal excision in MRI-defined poor-risk rectal cancer: a phase 2 trial. *Lancet Oncol*. 2010 Mar;11(3):241–8.
- [18] Peeters KC, van de Velde CJ, Leer JW, et al., Late side effects of short-course preoperative radiotherapy combined with total mesorectal excision for rectal cancer: increased bowel dysfunction in irradiated patients—a Dutch colorectal cancer group study. *J Clin Oncol*. 2005;23(25):6199–206.
- [19] Lange MM, den Dulk M, Bossema ER et al., Risk factors for faecal incontinence after rectal cancer treatment. Cooperative Clinical Investigators of the Dutch Total Mesorectal Excision Trial. *Br J Surg*. 2007;94(10):1278–84.
- [20] Birgisson H, Pahlman L, Gunnarsson U, Glimelius B. Occurrence of second cancers in patients treated with radiotherapy for rectal cancer. *J Clin Oncol* 2005;23: 6126–31.
- [21] Taylor FG, Quirke P, Heald RJ, et al., for the MERCURY study group. Preoperative High-resolution Magnetic Resonance Imaging Can Identify Good Prognosis Stage I, II, and III Rectal Cancer Best Managed by Surgery Alone: A Prospective, Multicenter, European Study That Recruited Consecutive Patients With Rectal Cancer. *Ann Surg*. 2011;253(4):711–9.
- [22] Frasson M, Garcia-Granero E, Roda D, et al., Preoperative chemoradiation may not always be needed for patients with T3 and T2N+ rectal cancer. *Cancer*. 2011 Jan 24. doi: 10.1002/cncr.25866. [Epub ahead of print].
- [23] Mathis KL, Larson DW, Dozois EJ, et al., Outcomes following surgery without radiotherapy for rectal cancer. *Br J Surg*. 2012;99(1):137–43.
- [24] Cercek A, Weiser MR, Goodman KA, et al., Complete pathological response in the primary of rectal or colon cancer treated with FOLFOX without radiation. *J Clin Oncol* 2010; 28: 15S suppl (May 20 Supplement): 297s (abstract 3649).
- [25] Schrag D, Weiser MR, Goodman KA, et al., Neoadjuvant FOLFOX-bev, without radiation for locally advanced rectal cancer. *J Clin Oncol* 2010; 28:15S_suppl (May 20 Supplement) 263s (abstract 3511).
- [26] Ishii Y, Hasegawa H, Endo T, Et al., Medium-term results of neoadjuvant systemic chemotherapy using irinotecan, 5-fluorouracil, and leucovorin in patients with locally advanced rectal cancer. *Eur J Surg Oncol*. 2010;36(11):1061–5.
- [27] Fernández-Martos C, Safont M, Feliu J, et al., Induction chemotherapy with or without chemoradiation in intermediate-risk rectal cancer patients defined by magnetic resonance imaging (MRI): A GEMCAD study. *J Clin Oncol*. 2010;28:15s (suppl abstract TPS 196).

PG 1.04 **SPEAKER ABSTRACT**
How to select the appropriate surgical approach in rectal cancer

T. Holm. Karolinska Universitetssjukhuset, Stockholm, Sweden

Abstract not available.

Thursday, 22 March, 10:30–12:00

Session II. Individualising Therapy in Colorectal Cancer

PG 2.01 **SPEAKER ABSTRACT**
Differentiating colon cancer by clinical criteria

E. Van Cutsem. Katholieke Universiteit Leuven, Leuven, Belgium

Abstract not available.

PG 2.02 **SPEAKER ABSTRACT**
Colorectal cancer with synchronous liver metastases

T. Ruers. Surgical Oncology, The Netherlands Cancer Institute, Amsterdam, Netherlands

This lecture will concentrate the on treatment strategy in patients that present with stage IV primary colorectal cancer. In patients with asymptomatic stage IV colon cancer and irresectable metastatic disease the most optimal treatment strategy remains controversial. Resection of the primary tumor may lead to high morbidity rates in malnourished patients, while on the other hand conservative or systemic treatment without resection of the primary tumor may still harbor the risk of bowel obstruction or tumor bleeding. Meta-analysis of mainly retrospective studies indicates, however, that conservative treatment and start of palliative chemotherapy may be save and leads to clinical symptoms of bowel obstruction in only a small minority of patients (14%). On the other hand several studies mention that colon resection may lead to surgical mortality in up to 5–10% of the patients. The results from a recent meta-analysis suggest that for patients with stage IV incurable colon cancer, resection of the asymptomatic primary tumor provides only minimal palliative benefit, can give rise to major morbidity and mortality, and may potentially delay the administration of systemic chemotherapy. Providing asymptomatic disease, initial resection seems not absolutely indicated and may mainly be reserved for the small proportion of patients who may develop complications due to the presence of primary tumor. On the other hand, when initial chemotherapy is started and incurable stage IV disease is converted into potentially curative disease, resection of both the primary tumor and its metastases should certainly be considered. Another debate concentrates on the treatment policy in patients with rectal cancer and operable colorectal liver metastases. The original treatment order in these patients consist of initial rectal resection followed by liver resection. Several group, however, make a clear statement for the reverse sequence of treatment and opt for a liver first approach. Recently, also another approach was advocated in which the conventional 6 week chemoradiation course was replaced by a one week (5 × 5 Gy) radiotherapy course followed by 6 weeks chemotherapy for optimal chemotherapy treatment of metastatic disease. Subsequently, initial rectal or initial liver resection was planned. The different treatment options for patients with synchronous colorectal liver metastases will be extensively discussed.